A secondary analysis of the SUMMIT trial indicates that tirzepatide, when used in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), decreases blood pressure and blood volume. It also improves cardiovascular function and reduces systemic inflammation.
In a secondary analysis of the SUMMIT trial, patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who were treated with tirzepatide showed reduced systolic blood pressure and decreased blood volume. The treatment also correlated with lower levels of microalbuminuria, improved cardiovascular quality of life, and increased walking distance. Additionally, reduced C-reactive protein levels were associated with lower troponin T levels and improved walking distance.
These findings suggest that tirzepatide reduces circulatory volume-pressure overload, systemic inflammation, and cardiovascular-kidney end-organ injury
Tirzepatide Heart Failure Preserved Ejection Fraction Obesity SUMMIT Trial Circulatory Overload
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Tirzepatide Reduces Heart Failure Events in HFpEF With ObesitySUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction and obesity.
Read more »
Tirzepatide shows powerful diabetes-prevention effect in three-year trialTirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study.
Read more »
Tirzepatide Slashes Progression From Prediabetes to T2DAt 3 years in SURMOUNT-1, more than 90% of people remained diabetes-free with tirzepatide and maintained their initial weight loss, but the benefits reverted after the drug was stopped.
Read more »
Will Cullen Hart, Beloved Member of Olivia Tremor Control and Circulatory System, Dead at 53Will Cullen Hart, member of bands Olivia Tremor Control and Circulatory System, died of natural causes at age 53.
Read more »
Nurse's death linked to weight-loss drug Mounjaro approved on NHSSusan McGowan from North Lanarkshire died two weeks after taking the drug tirzepatide, brand name Mounjaro.
Read more »
FDA Updates GLP-1 Label with Pulmonary Aspiration WarningThe new warning affects labels for drugs made with semaglutide, liraglutide, and tirzepatide.
Read more »